Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
Zaenker C
France
Research Article
Tolerance and Efficacy of Fampyra® in Real-Life Cohort of Patients with Multiple Sclerosis
Author(s): Ongagna JC, Berthe C, Courtois S, Gaultier C, Kopf A, Fleury M-C, Benoilid A, Collongues N, Blanc F, Zaenker C and de Seze JOngagna JC, Berthe C, Courtois S, Gaultier C, Kopf A, Fleury M-C, Benoilid A, Collongues N, Blanc F, Zaenker C and de Seze J
Background: Prolonged-release Fampridine is a selective potassium channel blocker licensed for the improvement of walking in adult patients diagnosed with multiple sclerosis (MS). The objective of this study was to evaluate the efficacy and safety of prolonged-release Fampridine in our regional MS cohort. Methods: Descriptive analysis data of Prolonged-release Fampridine (10 mg twice daily) patients were extracted from the European Database for Multiple Sclerosis (EDMUS) for the period since Fampridine became available in clinical practice. Data were collected on all patients in Alsace region of France. The patients had a mean EDSS score of 5.5 at baseline. The primary outcome was to determine the proportion of timed-walk responders at day compared to day 0 (baseline). The secondary outcome was the amplitude of this response in terms of .. View More»
DOI:
10.4172/2155-9899.1000355